Blog
RSS FeedPosted by Michael Wonder on 23 Jul 2025
ICER releases draft evidence report on treatment for non-cystic fibrosis bronchiectasis
23 July 2025 - Public comment period now open until 19 August 2025; requests to make oral comment during public ...
Posted by Michael Wonder on 18 Jul 2025
Public Summary Documents (first time decisions not to recommend and deferrals) – March 2025 PBAC meeting
18 July 2025 - The Public Summary Documents (first-time decisions not to recommend and deferrals) from the March 2025 PBAC ...
Posted by Michael Wonder on 18 Jul 2025
Outcome statement - June 2025 DUSC meeting
18 July 2025 - The outcome statement from the June 2025 DUSC meeting is now available. ...
Posted by Michael Wonder on 04 Jul 2025
Public Summary Documents - March 2025 PBAC meeting
4 July 2025 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the March 2025 ...
Posted by Michael Wonder on 03 Jul 2025
Release of provisional recommendations for expert advisory committees
1 July 2025 - We’re improving our processes, so that people can understand the outcome of expert advice to PHARMAC earlier. ...
Posted by Michael Wonder on 12 Jun 2025
EMA 2024 annual report is published
10 June 2025 - The EMA’s annual report 2024 published today gives insights into the Agency’s strategic priorities and contributions ...
Posted by Michael Wonder on 29 May 2025
ICER publishes evidence report on treatment for secondary progressive multiple sclerosis
29 May 2025 - There are significant uncertainties regarding long term efficacy of tolebrutinib; ICER estimates that treatment would achieve ...
Posted by Michael Wonder on 17 May 2025
Outcome statement - April 2025 DUSC meeting
16 May 2025 - The outcome statement from the April 2025 DUSC meeting is now available. ...
Posted by Michael Wonder on 27 Apr 2025
Public Summary Documents (first time decisions not to recommend and deferrals) – December 2024 PBAC meeting
24 April 2025 - The Public Summary Documents (first-time decisions not to recommend and deferrals) from the December 2024 PBAC meeting ...
Posted by Michael Wonder on 12 Apr 2025
Public Summary Documents – December 2024 PBAC meeting
11 April 2025 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the December 2024 PBAC ...
Posted by Michael Wonder on 27 Mar 2025
ICER publishes evidence report on treatment for retinitis pigmentosa
26 March 2025 - There are significant uncertainties regarding long term efficacy and durability of sonpiretigene isteparvovec; ICER estimates that ...
Posted by Michael Wonder on 21 Mar 2025
Public Summary Documents (first time rejections and deferrals)– November 2024 PBAC meeting
21 March 2025 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the November 2024 PBAC ...
Posted by Michael Wonder on 14 Mar 2025
DUSC utilisation analysis public release documents (October 2024)
14 March 2025 - The utilisation analysis public release documents from the October 2024 DUSC meeting are now available. ...
Posted by Michael Wonder on 07 Mar 2025
Public Summary Documents – November 2024 PBAC meeting
7 March 2025 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the November 2024 PBAC ...
Posted by Michael Wonder on 10 Feb 2025
ICER releases draft evidence report on treatment for advanced retinitis pigmentosa
6 February 2025 - Public comment period now open until 6 March 2025; requests to make oral comment during public ...